Polyphor AG (VTX:POLN) shareholders will doubtless be very grateful to see the share price up 53% in the last month. But that isn't much consolation to those who have suffered through the declines of ...

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But it should be a priority to avoid stomach churning catastrophes, wherever possible ...

Add Yahoo as a preferred source to see more of our stories on Google. ZURICH (Reuters) - Drugmaker Polyphor is hiring new managers and shifting focus after a trial of its top antibiotic hopeful proved ...

- The company plans to analyze progression free survival (PFS) for the study including all major sub-groups given data maturity for the overall population is reached - The company will neither seek ...

As a precautionary and prudent measure, the Board of Directors has decided to conduct the Extraordinary General Meeting 2021 without the physical presence of shareholders, in accordance with COVID-19 ...

ALLSCHWIL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN), announced today that it has received a new and second non-dilutive funding award from CARB-X (Combating ...

- Polyphor and EnBiotix have signed a merger agreement. - EnBiotix acquires Inhaled Murepavadin at an agreed valuation of USD 10 million in exchange for 2'599'655 of common shares of EnBiotix (15.4% ...

Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, December 22, 2020 Polyphor receives approval to ...

Reducing its headcount will enable Polyphor to stretch out its cash reserves. (Markus Spiske) Polyphor is closing its failed phase 3 breast cancer clinical trial and planning to lay off staff to lower ...

Swiss biotech Polyphor has seen its key cancer asset balixafortide fail a late-stage trial, leaving its future in the balance. That trial, a phase 3 test know as Fortress, was studying Polyphor’s GPCR ...

Balixafortide showed a clear anti-viral effect, different from remdesivir, in a 14-day laboratory (CPE) assay Balixafortide single agent treatment showed statistically significant reduction of viral ...

Please provide your email address to receive an email when new articles are posted on . ALLSCHWIL, Switzerland — Polyphor has entered into an exclusive worldwide discovery and license agreement with ...